Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
Lexicon Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.86|
|52 Week High||US$1.03|
|52 Week Low||US$9.65|
|1 Month Change||42.94%|
|3 Month Change||4.74%|
|1 Year Change||200.00%|
|3 Year Change||-53.63%|
|5 Year Change||-73.91%|
|Change since IPO||-96.30%|
Recent News & Updates
|LXRX||US Biotechs||US Market|
Return vs Industry: LXRX exceeded the US Biotechs industry which returned 25.7% over the past year.
Return vs Market: LXRX exceeded the US Market which returned 33.6% over the past year.
Stable Share Price: LXRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: LXRX's weekly volatility has decreased from 22% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Is Lexicon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LXRX ($4.86) is trading below our estimate of fair value ($49.58)
Significantly Below Fair Value: LXRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LXRX is good value based on its PE Ratio (18.4x) compared to the US Biotechs industry average (25.5x).
PE vs Market: LXRX is poor value based on its PE Ratio (18.4x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: LXRX is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: LXRX is overvalued based on its PB Ratio (5.1x) compared to the US Biotechs industry average (3.2x).
How is Lexicon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LXRX's forecast earnings growth (29.2% per year) is above the savings rate (2%).
Earnings vs Market: LXRX's earnings (29.2% per year) are forecast to grow faster than the US market (14.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: LXRX's revenue (57.7% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: LXRX's revenue (57.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LXRX's Return on Equity is forecast to be low in 3 years time (0.5%).
How has Lexicon Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LXRX has a large one-off gain of $128.1M impacting its June 30 2021 financial results.
Growing Profit Margin: LXRX's current net profit margins are higher than last year (12.3%).
Past Earnings Growth Analysis
Earnings Trend: LXRX has become profitable over the past 5 years, growing earnings by 30.4% per year.
Accelerating Growth: LXRX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LXRX had negative earnings growth (-3%) over the past year, making it difficult to compare to the Biotechs industry average (4.9%).
Return on Equity
High ROE: LXRX's Return on Equity (27.8%) is considered high.
How is Lexicon Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: LXRX's short term assets ($123.3M) exceed its short term liabilities ($32.8M).
Long Term Liabilities: LXRX's short term assets ($123.3M) exceed its long term liabilities ($1.6M).
Debt to Equity History and Analysis
Debt Level: LXRX's debt to equity ratio (8.5%) is considered satisfactory.
Reducing Debt: LXRX's debt to equity ratio has reduced from 47.1% to 8.5% over the past 5 years.
Debt Coverage: LXRX's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if LXRX's interest payments on its debt are well covered by EBIT.
What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LXRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LXRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LXRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lonnel Coats (56 yo)
Mr. Lonnel Coats has been the Chief Executive Officer and President of Lexicon Pharmaceuticals, Inc., since July 7, 2014. Mr. Coats served as an Executive Vice President, President of Americas Region at Ei...
CEO Compensation Analysis
Compensation vs Market: Lonnel's total compensation ($USD3.86M) is above average for companies of similar size in the US market ($USD2.33M).
Compensation vs Earnings: Lonnel's compensation has been consistent with company performance over the past year.
Experienced Management: LXRX's management team is seasoned and experienced (12.6 years average tenure).
Experienced Board: LXRX's board of directors are seasoned and experienced ( 14.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.9%.
Lexicon Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Lexicon Pharmaceuticals, Inc.
- Ticker: LXRX
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$702.146m
- Shares outstanding: 144.47m
- Website: https://www.lexpharma.com
Number of Employees
- Lexicon Pharmaceuticals, Inc.
- 8800 Technology Forest Place
- The Woodlands
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 00:46|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.